Promega Corporation announces ViaFect™ Transfection Reagent, a tool for efficient DNA transfer into a wide variety of cell lines, including challenging suspension cells and stem cell-derived lines. ViaFect Transfection Reagent allows researchers to develop transfection-based assays in the cell line most relevant for their biology of interest.
Induced pluripotent stem cell (iPSC)-derived cell models, such as Cellular Dynamics International's iCell® Cardiomyocytes, show robust transfection with ViaFect Transfection Reagent, enabling assays not possible with other reagents.
This low toxicity reagent allows cells to stay healthy and metabolically active during transfection-based experiments, even at low cell densities, facilitating experiments where extended application of a treatment is needed. Cell viabilities of greater than 90% are routinely observed following transfection with ViaFect Transfection Reagent.
ViaFect Transfection Reagent requires minimal optimization with a simple three-step protocol. It does not require removal of serum, removal of culture medium or washing after introduction of the reagent/DNA complex. ViaFect Transfection Reagent contains no animal-derived components.
A poster detailing results using ViaFect Transfection Reagent will also be presented at the Society for Laboratory Automation and Screening Conference and Exhibition to be held January 18th-22nd in San Diego, CA.